Kamal M, Wang XS, Shi Q, et al. - Researchers sought to obtain preliminary estimates of the effects of minocycline, an anti-inflammatory agent, on symptom reduction in advanced pancreatic cancer (PC) patients. In this phase 2, randomized, placebo-controlled trial, recruitment of 44 patients was done. Of these, 31 (71%) were evaluable for the primary efficacy analysis, with 18 received minocycline and 13 placebo. The most-severe symptoms reported by both groups were fatigue, pain, disturbed sleep, lack of appetite, and drowsiness. Overall, minocycline is identified to be safe for use in patients receiving treatment for PC. They recognized no known symptom reduction with minocycline on the major symptom burden linked with advanced PC compared with placebo. The study was significantly influenced by attrition due to rapid disease progression.